Management of type 2 diabetes: New and future developments in treatment

The Lancet

Volumn 378, Issue 9786, 2011, Pages 182-197

  Tahrani, Abd A ^a,b   Bailey, Clifford J ^c   Del Prato, Stefano ^d   Barnett, Anthony H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALBIGLUTIDE; ANTIDIABETIC AGENT; CJC 1134 PC; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; MIGLITOL; NATEGLINIDE; NEUTRAL INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; CARCINOMA; CELL DIFFERENTIATION; DIABETES CONTROL; DRUG DOSE COMPARISON; DRUG TARGETING; EDEMA; ENZYME INHIBITION; FLUID RETENTION; FRACTURE; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; GASTROPLASTY; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HALF LIFE TIME; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET DELTA CELL; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SIDE EFFECT; SLEEVE GASTRECTOMY; STOMACH BYPASS; SUSTAINED RELEASE FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 79960262492     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60207-9     Document Type: Review

References (133)

1. M Stumvoll, BJ Goldstein, TW van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333 1346
2. GM Reaven Role of insulin resistance in human disease Diabetes 37 1988 1595 1607 (Pubitemid 19004941)
3. SE Kahn, RL Hull, KM Utzschneider Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 444 2006 840 846 (Pubitemid 46024990)
4. R Burcelin, C Knauf, PD Cani Pancreatic alpha-cell dysfunction in diabetes Diabetes Metab 34 suppl 2 2008 S49 S55
5. H Mulder, C Nagorny, V Lyssenko, L Groop Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene Diabetologia 52 2009 1240 1249
6. MS Cooper, PM Stewart 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation J Clin Endocrinol Metab 94 2009 4645 4654
7. DJ Drucker, MA Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705 (Pubitemid 46048557)
8. RA DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
9. M Chen, RN Bergman, D Porte Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate J Clin Endocrinol Metab 67 1988 951 957
10. RA DeFronzo Glucose intolerance of aging. Evidence for tissue insensitivity to insulin Diabetes 28 1979 1095 1101 (Pubitemid 10215014)
11. M Ridderstrsle, L Groop Genetic dissection of type 2 diabetes Mol Cell Endocrinol 297 2009 10 17
12. KE Wellen, GS Hotamisligil Inflammation, stress, and diabetes J Clin Invest 115 2005 1111 1119 (Pubitemid 40629025)
13. Q Yang Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes Nature 436 2005 356 362 (Pubitemid 41065039)
14. L Rui, M Yuan, D Frantz, S Shoelson, MF White SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 J Biol Chem 277 2002 42394 42398 (Pubitemid 35257562)
15. SH Bates, RN Kulkarni, M Seifert, MG Myers Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis Cell Metab 1 2005 169 178 (Pubitemid 43960601)
16. RP Robertson, J Harmon, PO Tran, Y Tanaka, H Takahashi Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection Diabetes 52 2003 581 587 (Pubitemid 36323562)
17. RL Hull, GT Westermark, P Westermark, SE Kahn Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes J Clin Endocrinol Metab 89 2004 3629 3643 (Pubitemid 39071447)
18. P Marchetti, R Lupi, S Del Guerra, M Bugliani, L Marselli, U Boggi The beta-cell in human type 2 diabetes Adv Exp Med Biol 654 2010 501 514
19. JA Ehses, H Ellingsgaard, M Boni-Schnetzler, MY Donath Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction Arch Physiol Biochem 115 2009 240 247
20. MA Nauck, I Vardarli, CF Deacon, JJ Holst, JJ Meier Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54 2011 10 18
21. B Marcheva, KM Ramsey, ED Buhr et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes Nature 466 2010 627 631
22. CS Yang, CK Lam, M Chari et al. Hypothalamic AMP-activated protein kinase regulates glucose production Diabetes 59 2010 2435 2443
23. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
24. J Philippe, D Raccah Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 63 2009 321 332
25. AA Tahrani, MK Piya, A Kennedy, AH Barnett Glycaemic control in type 2 diabetes: targets and new therapies Pharmacol Ther 125 2010 328 361
26. AJ Krentz, CJ Bailey Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 653 2005 385 411 (Pubitemid 40227460)
27. CJ Bailey, RC Turner Metformin N Engl J Med 334 1996 574 579 (Pubitemid 126537875)
28. C Black, P Donnelly, L McIntyre, PL Royle, JP Shepherd, S Thomas Meglitinide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev 2 2007 CD004654.
29. SE Kahn, SM Haffner, MA Heise et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443 (Pubitemid 44903747)
30. H Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
31. SE Nissen, K Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
32. S Mudaliar, RR Henry Effects of incretin hormones on β-cell mass and function, body weight, and hepatic and myocardial function Am J Med 123 suppl 1 2010 S19 S27
33. LL Baggio, DJ Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157 (Pubitemid 46711096)
34. DF Kruger, MA Gloster Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data Drugs 64 2004 1419 1432 (Pubitemid 38980456)
35. RI Holt, AH Barnett, CJ Bailey Bromocriptine: old drug, new formulation and new indication Diabetes Obes Metab 12 2010 1048 1057
36. AH Barnett New treatments in type 2 diabetes - a focus on the incretin-based therapies Clin Endocrinol (Oxf) 70 2008 343 353
37. JJ Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439 (Pubitemid 350041474)
38. DA Stoffers, BM Desai, DD DeLeon, RA Simmons Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat Diabetes 52 2003 734 740 (Pubitemid 36323581)
39. BL Wajchenberg Beta-cell failure in diabetes and preservation by clinical treatment Endocr Rev 28 2007 187 218 (Pubitemid 46984834)
40. R Abu-Hamdah, A Rabiee, GS Meneilly, RP Shannon, DK Andersen, D Elahi The extrapancreatic effects of glucagon-like peptide-1 and related peptides J Clin Endocrinol Metab 94 2009 1843 1852
41. CF Deacon, AH Johnsen, JJ Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 80 1995 952 957
42. BD Green, PR Flatt Incretin hormone mimetics and analogues in diabetes therapeutics Best Pract Res Clin Endocrinol Metab 21 2007 497 516 (Pubitemid 350177567)
43. M Christensen, F Knop Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 10 2010 124 132
44. B Jose, AA Tahrani, MK Piya, AH Barnett Exenatide once weekly: clinical outcomes and patient satisfaction Patient Prefer Adherence 4 2010 313 324
45. DJ Drucker, JB Buse, K Taylor et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
46. D Kim, L MacConell, D Zhuang et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 2007 1487 1493 (Pubitemid 46871159)
47. K Iwamoto, R Nasu, A Yamamura et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes Endocr J 56 2009 951 962
48. M Diamant, L Van Gaal, S Stranks et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 375 2010 2234 2243
49. MA Nauck, RE Ratner, C Kapitza, R Berria, M Boldrin, R Balena Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study Diabetes Care 32 2009 1237 1243
50. R Ratner, M Nauck, C Kapitza, V Asnaghi, M Boldrin, R Balena Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study Diabet Med 27 2010 556 562
51. J Rosenstock, J Reusch, M Bush, F Yang, M Stewart Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing Diabetes Care 32 2009 1880 1886
52. JB Buse, DJ Drucker, KL Taylor et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 2010 1255 1261
53. M Trautmann, K Wilhelm, K Taylor, T Kim, D Zhuang, L Porter Exenatide once-weekly treatment elicits sustained glycaemic control and weight loss over 2 years Diabetologia 52 suppl 1 2009 S286 (abstr).
54. JH Best, KS Boye, RR Rubin, D Cao, TH Kim, M Peyrot Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily Diabet Med 26 2009 722 728
55. D Chen, J Liao, N Li et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice Proc Natl Acad Sci USA 104 2007 943 948 (Pubitemid 46154716)
56. LB Knudsen, D Kiel, M Teng et al. Small-molecule agonists for the glucagon-like peptide 1 receptor Proc Natl Acad USA 104 2007 937 942 (Pubitemid 46154715)
57. Arena Arena Pharmaceuticals announces APD668 initial clinical study results suggest glucose-dependent insulinotropic receptors may improve glucose control in patients with type 2 diabetes http://invest.arenapharm.com/ releasedetail.cfm?ReleaseID=320208 2008 (accessed May 16, 2011).
58. T Heise, EU Graefe-Mody, S Huttner, A Ring, D Trommeshauser, KA Dugi Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 11 2009 786 794
59. Barnett AH, Harper R, Toorawa R, Patel S, Woerle HJ. Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. European Association for the Study of Diabetes; Stockholm, Sweden; Sept 20-24, 2010. 823.
60. Lewin AJ, Arvay L, Liu D, Patel S, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. European Association for the Study of Diabetes; Stockholm, Sweden; Sept 20-24, 2010. 821.
61. MR Taskinen, J Rosenstock, I Tamminen et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 13 2011 65 74
62. Graefe-Mody U, Friedrich C, Port A, et al. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment. European Association for the Study of Diabetes; Stockholm, Sweden; Sept 20-24, 2010. 822.
63. RA DeFronzo, PR Fleck, CA Wilson, Q Mekki Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 31 2008 2315 2317
64. MA Nauck, GC Ellis, PR Fleck, CA Wilson, Q Mekki Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study Int J Clin Pract 63 2009 46 55
65. RE Pratley, MS Kipnes, PR Fleck, C Wilson, Q Mekki Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabetes Obes Metab 11 2009 167 176
66. J Rosenstock, MS Rendell, JL Gross, PR Fleck, CA Wilson, Q Mekki Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia Diabetes Obes Metab 11 2009 1145 1152
67. CJ Bailey New therapies for diabesity Curr Diab Rep 9 2009 360 367
68. M Pal Recent advances in glucokinase activators for the treatment of type 2 diabetes Drug Discov Today 14 2009 784 792
69. RC Bonadonna, T Heise, C Arbet-Engels et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study J Clin Endocrinol Metab 95 2010 5028 5036
70. L Agius New hepatic targets for glycaemic control in diabetes Best Pract Res Clin Endocrinol Metab 21 2007 587 605 (Pubitemid 350177566)
71. J Grimsby, R Sarabu, WL Corbett et al. Allosteric activators of glucokinase: potential role in diabetes therapy Science 301 2003 370 373 (Pubitemid 36877072)
72. DH Kozian, A Barthel, E Cousin et al. Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study Horm Metab Res 42 2010 502 506
73. R Lee Kennedy, V Vangaveti, G Jarrod, V Shashidhar, V Shashidhar, BT Baune Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications Therap Adv Endocrinol Metab 1 2010 165 175
74. T Froud, RN Faradji, A Pileggi et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects Transplantation 86 2008 36 45
75. R Lupi, S Del Guerra, R Mancarella et al. Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger Diabetes Metab 33 2007 340 345 (Pubitemid 350030903)
76. JA Ehses, G Lacraz, MH Giroix et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat Proc Natl Acad Sci USA 106 2009 13998 14003
77. S Del Prato, P Marchetti Beta- and alpha-cell dysfunction in type 2 diabetes Horm Metab Res 36 2004 775 781 (Pubitemid 40115899)
78. RW Gelling, XQ Du, DS Dichmann et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice Proc Natl Acad Sci USA 100 2003 1438 1443 (Pubitemid 36184020)
79. P Madsen, J Kodra, C Behrens et al. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties J Med Chem 52 2009 2989 3000
80. J Kodra, AS Jørgensen, B Andersen et al. Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor J Med Chem 51 2008 5387 5396
81. N Rivera, CA Everett-Grueter, DS Edgerton et al. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog J Pharmacol Exp Ther 321 2007 743 752 (Pubitemid 46624501)
82. Y Lau, P Ma, L Gibiansky et al. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice AAPS J 11 2009 700 709
83. TH Claus, CQ Pan, JM Buxton et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes J Endocrinol 192 2007 371 380 (Pubitemid 46444438)
84. A Pocai, PE Carrington, JR Adams et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 58 2009 2258 2266
85. K Wynne, AJ Park, CJ Small et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial Int J Obes 30 2006 1729 1736 (Pubitemid 44863404)
86. CJ Bailey Treating insulin resistance: future prospects Diab Vasc Dis Res 4 2007 20 31 (Pubitemid 46649070)
87. B Zhang, G Salituro, D Szalkowski et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice Science 284 1999 974 977 (Pubitemid 29288438)
88. HJ Tsai, SY Chou A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation J Biomed Sci 16 2009 68
89. VP Manchem, ID Goldfine, RA Kohanski et al. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo Diabetes 50 2001 824 830 (Pubitemid 32242640)
90. S Koren, IG Fantus Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus Best Pract Res Clin Endocrinol Metab 21 2007 621 640 (Pubitemid 350185860)
91. S Garcia-Vicente, F Yraola, L Marti et al. Oral insulin-mimetic compounds that act independently of insulin Diabetes 56 2007 486 493
92. JE Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 2010 136 142
93. EM Wright, BA Hirayama, DF Loo Active sugar transport in health and disease J Intern Med 261 2007 32 43 (Pubitemid 46046470)
94. CJ Bailey, C Day SGLT2 inhibitors: glucuretic treatment for type 2 diabetes Br J Diab Vasc Dis 10 2010 193 199
95. R Santer, J Calado Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target Clin J Am Soc Nephrol 5 2010 133 141
96. EC Chao, RR Henry SGLT2 inhibition-a novel strategy for diabetes treatment Nat Rev Drug Discov 9 2010 551 559
97. CJ Bailey, JL Gross, A Pieters, A Bastien, JF List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
98. L Zhang, Y Feng, J List, S Kasichayanula, M Pfister Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes Metab 12 2010 510 516
99. JF List, V Woo, E Morales, W Tang, FT Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
100. JPH Wilding, P Norwood, C T'joen, A Bastien, JF List, FT Fiedorek A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 32 2009 1656 1662
101. E Ferrannini, SJ Ramos, A Salsali, W Tang, JF List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
102. Wilding JPH, Woo V, Pahor A, Sugg J, Langkilde A, Parikh S. Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. European Association for the Study of Diabetes; Stockholm, Sweden; Sept 20-24, 2010. 871.
103. Nauck M, Del Prato S Rohwedder K, Elze M, Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial. European Association for the Study of Diabetes; Stockholm, Sweden; Sept 20-24, 2010. 241.
104. AL Gloyn Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy Hum Mutat 22 2003 353 362 (Pubitemid 37346107)
105. C Mues, J Zhou, KN Manolopoulos et al. Regulation of Glucose-6- phosphatase gene expression by insulin and metformin Horm Metab Res 41 2009 730 735
106. E Floettmann, L Gregory, J Teague et al. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases Toxicol Pathol 38 2010 393 401
107. PR Flatt, CJ Bailey, BD Green Recent advances in antidiabetic drug therapies targeting the enteroinsular axis Curr Drug Metab 10 2009 125 137
108. JW Tomlinson, J Moore, MS Cooper et al. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines Endocrinology 142 2001 1982 1989 (Pubitemid 32405956)
109. SA Morgan, M Sherlock, LL Gathercole et al. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle Diabetes 58 2009 2506 2515
110. J Rosenstock, S Banarer, VA Fonseca et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor incb13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 33 2010 1516 1522
111. AH Barnett Redefining the role of thiazolidinediones in the management of type 2 diabetes Vasc Health Risk Manag 5 2009 141 151
112. P Sanwald-Ducray, X Liogier D'ardhuy, C Jamois, L Banken Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study Clin Pharmacol Ther 88 2010 197 203
113. RR Henry, AM Lincoff, S Mudaliar, M Rabbia, C Chognot, M Herz Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
114. D Jones Potential remains for PPAR-targeted drugs Nat Rev Drug Discov 9 2010 668 669
115. AH Cincotta, AH Meier, JM Cincotta Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opin Investig Drugs 8 1999 1683 1707 (Pubitemid 29460532)
116. AH Barnett, C Chapman, K Gailer, CJ Hayter Effect of bromocriptine on maturity onset diabetes Postgrad Med J 56 1980 11 14 (Pubitemid 10214677)
117. CK Lam, M Chari, TK Lam CNS regulation of glucose homeostasis Physiology (Bethesda) 24 2009 159 170
118. JM Gaziano, AH Cincotta, CM O'Connor et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes Diabetes Care 33 2010 1503 1508
119. VA Fonseca, Y Handelsman, B Staels Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence Diabetes Obes Metab 12 2010 384 392
120. WJ Pories, MS Swanson, KG MacDonald et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus Ann Surg 222 1995 339 352
121. L Sjostrom, AK Lindroos, M Peltonen et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery N Engl J Med 351 2004 2683 2693 (Pubitemid 39665322)
122. EJ DeMaria Bariatric surgery for morbid obesity N Engl J Med 356 2007 2176 2183
123. H Buchwald, R Estok, K Fahrbach et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis Am J Med 122 2009 248 256
124. JB Dixon, PE O'Brien, J Playfair et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial JAMA 299 2008 316 323 (Pubitemid 351159368)
125. D Pournaras, C le Roux Obesity, gut hormones, and bariatric surgery World J Surg 33 2009 1983 1988
126. G Mingrone, G Nolfe, G Castagneto Gissey et al. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion Diabetologia 52 2009 873 881
127. M Bueter, C Löwenstein, T Olbers et al. Gastric bypass increases energy expenditure in rats Gastroenterology 138 2010 1845 1853
128. AD Miras, CW Le Roux Bariatric surgery and taste: novel mechanisms of weight loss Curr Opin Gastroenterol 26 2010 140 145
129. R Sturm Increases in morbid obesity in the USA: 2000-2005 Public Health 121 2007 492 496 (Pubitemid 46895458)
130. 2 Diabetologia 52 2009 1027 1030
131. A DePaula, A Stival, A Halpern, S Vencio Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients Obes Surg 21 2011 668 675
132. R Schouten, CS Rijs, ND Bouvy et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery Ann Surg 251 2010 236 243
133. JB Buse, S Caprio, WT Cefalu et al. How do we define cure of diabetes? Diabetes Care 32 2009 2133 2135